British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca set up a clinical data and insights (CDI) division in Bangalore for data-related management of its clinical trials.
The CDI is a critical advancement that will support a growing global portfolio and build on internal data expertise. It will function across therapy areas and portfolios, supporting early and late-stage clinical programs from Phase 1 to Phase 3, with an integrated end-to-end approach for clinical data, analytics, insights and risk management, said a company statement.
AstraZeneca VP, and global head of Clinical Data & Insights Natalie Fishburn said, “The establishment of the CDI division in India is key to our strategic vision of being industry leaders in this space. Clinical data and insight solutions enable pharmaceutical organizations such as ours to gain in-depth visibility into the patient’s journey by extracting actionable insights from disparate data sources.”
